Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

J, Huober; PA, Fasching; M, Barsoum; L, Petruzelka; D, Wallwiener; C, Thomssen; T, Reimer; S, Paepke; HA, Azim; V, Ragosch; E, Kubista; AK, Baumgärtner; MW, Beckmann; C, May; I, Nimmrich; N, Harbeck

doi:10.1016/j.breast.2011.07.006

Public

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

Shared by NobleBlocks on Sep 8, 2011 • 12:00 AM UTC

Authors:

Huober J

Fasching PA

Barsoum M

Abstract

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!